CD8A and neoplasm: The PD-1 receptor transmits inhibitory signals upon binding to its ligand, decreases TCR signaling pathway phosphorylation, decreases TCR activation downstream of the receptor, and protects tumor cells from CD8+ T lymphocyte cracking by inhibiting T lymphocyte proliferation and function 45.